Navigation Links
Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds
Date:1/13/2014

ique structural and physiochemical properties. Unlike related compounds, PIXUVRI forms stable DNA adducts and in preclinical models has superior anti-lymphoma activity compared to related compounds. PIXUVRI was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite -- both of which are the putative mechanisms for anthracycline induced acute and chronic cardiotoxicity.  These novel pharmacologic properties allow PIXUVRI to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity.

In May 2012, the European Commission (EC) granted conditional marketing authorization for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL. The benefit of PIXUVRI treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy. The Summary of Product Characteristics (SmPC) has the full prescribing information, including the safety and efficacy profile of PIXUVRI in the approved indication. The SmPC is available at www.pixuvri.eu.

CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. PIXUVRI does not have marketing approval in the United States.

About Opaxio

Opaxio™ (paclitaxel poliglumex) is an investigational, biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, paclitaxel is inactive, potentially sparing normal tissue's exposure to high levels of paclitaxel and its associated toxicities. Blood vessels in tumor tis
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
2. PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
3. ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
4. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
5. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
6. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
7. Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. G1 Therapeutics to Present at Biotech Showcase 2014
9. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
10. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
11. Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... SHANGHAI , Nov. 26, 2014  CARsgen, a ... (CAR-T) cell immunotherapy to treat a variety of cancers, ... led by BVCF, a China -based ... an immunotherapy company focused on the development of new ... collaboration with Shanghai Cancer Institute and Shanghai Renji Hospital, ...
(Date:11/26/2014)... N.C. , Nov. 25, 2014  At the ... Antonio this October, KaVo Kerr Group was ... Technology Expo, offering attendees the opportunity to see and ... well-respected key opinion leaders deliver lectures on the latest ... Group products include the new DEXIS CariVu Caries Detection ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... , Jan. 29 EP Global Communications, Inc. ... ), the parent company of Exceptional Parent ( EP ) ... has joined the EPGL Advisory Board. Dr. DeFelice is one of the ... term "nutraceutical."  , "This addition to our team of experts will ...
... , PITTSBURGH , Jan. 29 ... subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. ... Application (ANDA) for Polyethylene Glycol 3350 and Electrolytes for Oral ... , Polyethylene Glycol 3350 and Electrolytes for Oral Solution ...
Cached Medicine Technology:EP Global Communications, Inc. Welcomes Stephen DeFelice, MD, to Advisory Board 2EP Global Communications, Inc. Welcomes Stephen DeFelice, MD, to Advisory Board 3Mylan Receives Approval for Generic Version of GoLytely(R) 2
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Not only ... create products free of petroleum, parabens and other cancer-causing ... that fund research, education and awareness programs that help ... staff and owners have raised an incredible, record-breaking contribution ... the Cure, sales of the Sweet Red Rose Whip ...
(Date:11/28/2014)... Angeles, CA (PRWEB) November 28, 2014 ... online, reported during the hugely popular, 2014 ... the antismoking organization Truth launched ground-breaking celebrity centered ... 18-49. The MTV viewership figures were estimated by ... Truth antismoking ads placed the spotlight on celebrities ...
(Date:11/28/2014)... 28, 2014 A newly released article ... overview of the influenza virus that will soon be spreading ... , The article begins with a brief explanation of what ... It reminds families that children under the age of 5, ... chronic diseases, such as heart and lung diseases, asthma, or ...
(Date:11/28/2014)... November 28, 2014 Patten Pecans, based ... grown. With those passions driving them, they've added a ... Having tried other pecans oils, they've found this ... to be exceptionally flavorful, retaining the buttery pecan notes ... nutritional benefits found in pecans nuts is ...
Breaking Medicine News(10 mins):Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... procedures, survey shows , FRIDAY, July 31 (HealthDay News) -- ... visited a plastic surgeon for a "makeover" -- a ... around her lips and at the corners of her mouth. ... might lose her competitive edge in a tightening job market. ...
... , , WASHINGTON, July 31 ... Tobacco-Free Kids: , , (Logo: ... Council has taken an important step to protect the District,s kids and ... tax by 50 cents to $2.50 per pack - the seventh highest ...
... Fla., July 31 Sanofi-aventis US announced yesterday that the FDA ... in the USA. It offers results that last for years. Dr ... the product while abroad. It was approved in Europe(CE) for over ... global pharmaceutical company. The FDA approval is based on results from ...
... Md., July 31 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, today,announced ... results,on Monday, August 10, 2009, before the market opens. Management ... 10, 2009 to discuss financial results. , ...
... , , ... Administration (FDA) today approved the first and only antipsychotic for ... were approved for the acute treatment of schizoaffective disorder either ... INVEGA(R) was approved in 2006 for the treatment of schizophrenia. ...
... , Campaign Officially Launches ... months of college students and others wrestling with the creative challenge ... for its nationwide sign design contest. The victors are Kelsey Hazzard, ... law school this fall at the University of Virginia, and Christina ...
Cached Medicine News:Health News:Plastic Surgeons Stay Busy in Recession 2Health News:Plastic Surgeons Stay Busy in Recession 3Health News:District of Columbia Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:Chindex International, Inc. to Report First Quarter Fiscal 2010 Financial Results 2Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 2Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 3Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 4Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 5Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 6Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 7Health News:CandleInTheWindow.org Announces $1000 Scholarship Prize Winners 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: